INTRAVACC B.V. - DEVELOPMENT OF AN INTRANASAL VACCINE AGAINST GONORRHEA BASED ON OUTER MEMBRANE VESICLES COMBINED WITH SUSTAINED-RELEASE MICROSPHERES CONTAINING RECOMBINANT HUMAN INTERLEUKIN-12.

On Dec 9, 2025, Department of Health and Human Services obligated $6,612,767 to INTRAVACC B.V. for development of an intranasal vaccine against gonorrhea based on outer membrane vesicles combined with sustained-release microspheres containing recombinant human interleukin-12.. The award is classified under NAICS 541715 — RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) and issued as a cost no fee contract. Competition extent: full and open competition with 10 offers received. The procurement used a NO SET ASIDE USED. set-aside. The contract is scheduled through Dec 8, 2026 — approximately 8 months remaining. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541715 — related awards are listed below.